Results 151 to 160 of about 199,466 (288)
Deep Optical Emission-line Images of Nine Known and Three New Galactic Supernova Remnants
Deep optical emission-line images are presented for nine known plus three new Galactic supernova remnants (SNRs), all but one having at least one angular dimension >1°.
Robert A. Fesen+16 more
doaj +1 more source
Comparison of Solar Energetic Particle Flux Measurements by CRaTER and GOES
Abstract The Cosmic Ray Telescope for the Effects of Radiation (CRaTER) aboard the Lunar Reconnaissance Orbiter spacecraft has been operating in lunar orbit since 2009. CRaTER data provide a long‐term record of the near‐Moon radiation environment that is relevant to human exploration.
C. Zeitlin+8 more
wiley +1 more source
Supernova remnants (SNRs) exhibit varying degrees of anisotropy, which have been extensively modeled using numerical methods. We implement a technique to measure anisotropies in SNRs by calculating power spectra from their high-resolution images. To test
Soham Mandal+3 more
doaj +1 more source
Supernova 1987A: The Birth of a Supernova Remnant [PDF]
SummaryI describe and interpret observations of the rapidly developing impact of the debris of SN1987A with its circumstellar ring.
openaire +2 more sources
Nowcasting Solar Energetic Particle Events for Mars Missions
Abstract In addition to the omnipresent Galactic Cosmic Rays, sudden Solar Energetic Particle (SEP) events present considerable health hazards for manned space missions. These events not only contribute to an increased long‐term cancer risk, but can, in extreme cases, cause acute radiation syndromes.
Jan Leo Löwe+10 more
wiley +1 more source
The maximum energy of electrons in supernova remnant (SNR) shocks is typically limited by radiative losses, where the synchrotron cooling time equals the acceleration time.
Vincenzo Sapienza+7 more
doaj +1 more source
Continuous solutions of cosmic-rays and waves in astrophysical environments. [PDF]
Irshad K+5 more
europepmc +1 more source
ABSTRACT Background Pre‐exposure prophylaxis with tixagevimab‐cilgavimab significantly reduced severe COVID‐19 outcomes in high‐risk individuals during the pre‐Omicron era (PROVENT trial). However, efficacy in patients with haematological malignancies (HM) was underreported.
Manuela A. Hoechstetter+6 more
wiley +1 more source
Supernovae and the Arrow of Time. [PDF]
Abarzhi SI+4 more
europepmc +1 more source